Sandoz Wants Big Biosimilar Case Sent To District Court
Sandoz Inc. on Thursday asked the Federal Circuit to send its biosimilars brawl with Amgen Inc. back to the district court level, arguing that an issue raised by the U.S. Supreme...To view the full article, register now.
Already a subscriber? Click here to view full article